- Language: English
- Published: August 2012
Global Hemophilia Treatment Market 2010-2014
- ID: 2069170
- February 2012
- Region: Global
- 31 pages
TechNavio’s analysts forecast the Global Hemophilia Treatment market to grow at a CAGR of 5.5 percent over the period 2010–2014. One of the key factors contributing to this market growth is hemophilia is an inherited disorder. The Global Hemophilia Treatment market has also been witnessing the trend of home hemophilia treatment therapy. However, high cost of treatment could pose a challenge to the growth of this market.
TechNavio’s report, Global Hemophilia Treatment Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hemophilia Treatment market landscape and its growth prospects in the coming years.
This report includes treatments for hemophilia A, B, and C, namely, recombinant factor VIII and coagulation factor IX, and Desmopressin (DDAVP) which stimulates the release of factor VIII and also increases the level of proteins in the blood.
Key vendors dominating this market space include Baxter Healthcare Corp., Novo Nordisk A/S, Bayer Healthcare Pharmaceuticals Inc., and Pfizer Inc.
Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
TechNavio Announces the Publication of its Report: Global Hemophilia Treatment Market 2010–2014
TechNavio today published its report Global Hemophilia Treatment Market 2010–2014. The report aids decision makers’ understanding of the present and the future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said, “A key driver for the growth of this market is various government comprehensive care programs running for the treatment of hemophilia. These programs aim to provide improved health, decreased hospitalization accompanied by decreased costs of care. Moreover, vendors are also supporting such comprehensive care programs in the form of campaigns. For instance, Novo Nordisk supports the "It's Time for a Cure” campaign among various other programs for the bleeding disorders community.”
According to the report, mergers and acquisitions has become the core growth strategy for many healthcare vendors. It has become the growth avenue for product expansion, competitive advantage, and greater market share. The Global Hemophilia Treatment market is also witnessing a similar trend of strategic alliance for increasing the market share and global presence. For instance, in 2010, Baxter entered into a definitive agreement to acquire all the hemophilia-related assets of Archemix, a privately held biopharmaceutical company.
The report also discusses key challenges in this market including possible side effects of this form of treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Baxter Healthcare Corp.
11.2 Novo Nordisk A/S
11.3 Bayer Healthcare Pharmaceuticals Inc.
11.4 Pfizer Inc.
List of Exhibits:
Exhibit 1: Global Hemophilia Treatment Market 2010–2014 (US$ billion)
Exhibit 2: Global Hemophilia Treatment Market by Product Segmentation 2010
Exhibit 3: Global Hemophilia Treatment Market by Geographical Segmentation 2010
Exhibit 4: Global Hemophilia Treatment Market by Vendor Segmentation 2010
- Baxter Healthcare Corp.
- Novo Nordisk A/S
- Bayer Healthcare Pharmaceuticals Inc.
- Pfizer Inc.